Gyre Therapeutics Inc. (GYRE)
NASDAQ: GYRE
· Real-Time Price · USD
9.37
-0.39 (-4.00%)
At close: May 01, 2025, 3:59 PM
9.34
-0.32%
After-hours: May 01, 2025, 04:20 PM EDT
-4.00% (1D)
Bid | 9.21 |
Market Cap | 878.37M |
Revenue (ttm) | 105.76M |
Net Income (ttm) | 15.96M |
EPS (ttm) | 0.05 |
PE Ratio (ttm) | 187.4 |
Forward PE | 6.8 |
Analyst | n/a |
Ask | 9.34 |
Volume | 99,539 |
Avg. Volume (20D) | 146,516 |
Open | 9.84 |
Previous Close | 9.76 |
Day's Range | 9.28 - 9.90 |
52-Week Range | 6.11 - 19.00 |
Beta | 2.41 |
About GYRE
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney dise...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 12, 2006
Employees 579
Stock Exchange NASDAQ
Ticker Symbol GYRE
Website https://www.gyretx.com
1 month ago
-30.21%
Gyre Therapeutics shares are trading lower. The co...
Unlock content with
Pro Subscription
5 months ago
-9.56%
Gyre Therapeutics shares are trading lower after the company reported a year-over-year decline in Q3 financial results.